XV454, a Novel Nonpeptide Small-Molecule Platelet GIIb/IIIa Antagonist with Comparable Platelet αIIbβ3-Binding Kinetics to c7E3
Authors:
- Shaker A. MousaShaker A. Mousa
- Mark ForsytheMFMark Forsythe
- Jeffrey BozarthJBJeffrey Bozarth
- Ashraf YoussefAYAshraf Youssef
- John WityakJWJohn Wityak
- Rick OlsonRORick Olson
- Thais SieleckiTSThais Sielecki
- 1 November 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 32 (5) , 736-744
Abstract
XV454 demonstrated high potency (IC50 = 14-25 nM) in inhibiting human platelet aggregation induced by adenosine diphosphate (ADP, 10 μM), thrombin receptor agonist peptide (TRAP) (10 μM), or collagen (20 μg/ml). XV454 exhibited a high degree of selectivity for platelet aIIbβ3 in comparison with c7E3, which is a nonspecific antagonist for both aIIbβ3 and avb3. Both XV454 and c7E3 bind with high affinity to either activated (A) or unactivated (U) human, baboon, or canine platelets. XV454 binds with a relatively higher affinity [Kd = 0.5 nM (A), 0.6 nM (U)] as compared with c7E3 [Kd = 9.1 nM (A), 9.2 (U) nM]. XV454 demonstrated a tight association with human, baboon, and, to a lesser extent, with canine platelets (t1/2 of dissociation = 110 ± 6, 80 ± 10, and 23 ± 2 min, respectively). Both c7E3 and XV454 associate tightly with a slower dissociation rate with unactivated human platelets: t1/2 of 42 and 116 min, respectively. In nonhuman primates, oral (0.1 mg/kg, p.o.) and intravenous (0.05 mg/kg, i.v. bolus administration of XV454 methyl ester prodrug resulted a long-lasting maximal antiplatelet efficacy for ≤72 h with significant but reversible prolongation of bleeding time and without effects on platelet count, clinical chemistry, or hemodynamic profile. In conclusion, XV454 represents a potent antiplatelet agent in inhibiting platelet aggregation along with a high affinity and relatively slow dissociation rate from human platelet GPIIb/IIIa receptors that allow a long-lasting antiplatelet efficacy after single i.v. or oral administration.Keywords
This publication has 19 references indexed in Scilit:
- GPIIb-IIIa: The responsive integrinCell, 1991
- Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications.Circulation, 1989
- Biochemical evidence of platelet activation in patients with persistent unstable anginaJACC, 1987
- Platelet Activation in Unstable Coronary DiseaseNew England Journal of Medicine, 1986
- Platelet Membrane Glycoprotein IIb/IIIa: Member of a Family of Arg-Gly-Asp—Specific Adhesion ReceptorsScience, 1986
- Role of platelets and thrombosis in coronary atherosclerotic disease and sudden deathJACC, 1985
- Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina.Heart, 1985
- Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: Direct evidence for enhanced platelet reactivity in vivoThe American Journal of Cardiology, 1981
- Platelet activation in clinical coronary artery disease and spasmAmerican Heart Journal, 1981
- Release of Prostaglandins and Thromboxane into the Coronary Circulation in Patients with Ischemic Heart DiseaseNew England Journal of Medicine, 1981